Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion.
Type-I interferon
head and neck cancer
ifnar1
stemness
sting1
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
4
1
2022
Statut:
epublish
Résumé
Type-I interferon (IFN-I) signaling is critical to maintaining antigen-presenting cell function for anti-tumor immunity. However, recent studies have suggested that IFN-I signaling may also contribute to more aggressive phenotypes, raising the possibility that IFN-I downstream signaling in cancer and myeloid cells may exert dichotomous functions.We analyzed the clinicopathologic correlation of cancer-specific IFN-I activation in 195 head and neck squamous cell carcinoma patients. We also characterized the immune impact of IFN-I receptor (IFNAR1)-deficiency in syngeneic tumor models using biochemistry, flow cytometry, and single-cell RNA-Seq. We stained HNSCC tissue microarrays with a sensitive IFN-I downstream signaling activation marker, MX1, and quantitated cancer cell-specific MX1 staining. Kaplan-Meier analysis revealed that MX1-high tumors exhibited worse survival, a phenotype that depends on the number of CD8
Identifiants
pubmed: 34858725
doi: 10.1080/2162402X.2021.1997385
pii: 1997385
pmc: PMC8632299
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1997385Subventions
Organisme : NCI NIH HHS
ID : U24 CA232979
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NIDCR NIH HHS
ID : U01 DE029255
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE021139
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE030691
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007413
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE026728
Pays : United States
Organisme : NIDCR NIH HHS
ID : R03 DE027399
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008600
Pays : United States
Organisme : NIDCR NIH HHS
ID : F31 DE028740
Pays : United States
Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
Y.L.L. licensed the NOOC1 model to Kerafast Inc. Y.L.L. is a co-founder and serves on the Scientific Advisory Board for Saros Therapeutics. The other authors declare no conflict of interest relevant to the current study. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Head Neck. 2016 Jul;38(7):1074-84
pubmed: 26879675
Cancer Res. 2016 Mar 1;76(5):1031-43
pubmed: 26676749
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Clin Cancer Res. 2020 Jan 1;26(1):290-300
pubmed: 31562203
Biomaterials. 2019 Jun;205:94-105
pubmed: 30909112
Cell Res. 2019 Oct;29(10):846-861
pubmed: 31481761
J Immunol. 2010 Aug 15;185(4):2116-24
pubmed: 20644163
Immunity. 2017 Aug 15;47(2):251-267.e7
pubmed: 28813658
Nat Nanotechnol. 2021 Nov;16(11):1260-1270
pubmed: 34594005
Clin Cancer Res. 2016 Jul 15;22(14):3571-81
pubmed: 26864211
Clin Cancer Res. 2018 Sep 1;24(17):4242-4255
pubmed: 29769207
Sci Transl Med. 2015 Apr 15;7(283):283ra52
pubmed: 25877890
Nat Med. 2014 Nov;20(11):1301-9
pubmed: 25344738
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33320840
Cancer Immunol Res. 2019 Nov;7(11):1760-1774
pubmed: 31624067
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Clin Invest. 2020 Apr 1;130(4):1635-1652
pubmed: 31874109
J Gen Virol. 2008 Jan;89(Pt 1):261-270
pubmed: 18089750
Oncogenesis. 2021 Jan 19;10(1):12
pubmed: 33468992
Cancer Immunol Res. 2016 Dec;4(12):1061-1071
pubmed: 27821498
Immunol Rev. 2019 Jul;290(1):24-38
pubmed: 31355488
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Biomaterials. 2018 May;163:67-75
pubmed: 29454236
Clin Chem. 2019 Jun;65(6):739-750
pubmed: 30593466
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
Int J Oral Sci. 2009 Sep;1(3):105-18
pubmed: 20695076
J Clin Invest. 2001 Nov;108(9):1331-9
pubmed: 11696578
J Clin Oncol. 2015 Oct 10;33(29):3235-42
pubmed: 26351338
Clin Cancer Res. 2018 Feb 15;24(4):896-905
pubmed: 29233903
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Genes Dev. 2017 Feb 15;31(4):353-369
pubmed: 28279982
Cell Stem Cell. 2020 Aug 6;27(2):238-253.e6
pubmed: 32697949
Oral Oncol. 2018 Jun;81:45-51
pubmed: 29884413
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73
pubmed: 19116269
Cancer Res. 2017 Nov 15;77(22):6353-6364
pubmed: 28904066
J Virol. 2007 Jul;81(14):7776-85
pubmed: 17494065
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Br J Cancer. 2019 Feb;120(3):306-316
pubmed: 30585254
Nat Nanotechnol. 2017 Jul;12(7):648-654
pubmed: 28436963
Nat Nanotechnol. 2019 Mar;14(3):269-278
pubmed: 30664751
Oncoimmunology. 2019 Apr 24;8(7):1593805
pubmed: 31143513
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
J Immunol. 2003 Dec 1;171(11):5853-64
pubmed: 14634095
J Exp Med. 2015 Aug 24;212(9):1345-60
pubmed: 26261266
J Virol. 1991 Feb;65(2):968-71
pubmed: 1702845
Immunity. 2018 Sep 18;49(3):490-503.e4
pubmed: 30170810
Nat Commun. 2020 Nov 30;11(1):6077
pubmed: 33257685
Cell Death Discov. 2020 May 15;6:36
pubmed: 32435511
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669